BTIG analyst Ryan Zimmerman maintained a Buy rating on Staar Surgical (STAA – Research Report) today and set a price target of $39.00. The company’s shares closed yesterday at $23.33.

Piper Sandler analyst Matthew O’Brien maintained a Hold rating on Staar Surgical (STAA – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $46.65.

STAAR Surgical Company's Q2 FY'23 earnings missed consensus estimates. The key revenue driver for STAA is its Implantable Collamer Lenses, which saw a 21% YoY increase in unit volumes. Despite ...

This company is led by a rockstar CEO that has a proven track record of turning not just STAA but other companies around. Business fundamentals have been improving over the past 7 years across ...

In recent trading, shares of Staar Surgical Co. (Symbol: STAA) have crossed above the average analyst 12-month target price of $108.50, changing hands for $111.58/share. When a stock reaches the ...

Investors in Staar Surgical Co. (Symbol: STAA) saw new options become available today, for the September 2023 expiration. One of the key data points that goes into the price an option buyer is ...

Attractive stocks have exceptional fundamentals. In the case of STAAR Surgical Company (NASDAQ:STAA), there's is a company with strong financial health as well as an optimistic future outlook.

Good day, ladies and gentlemen, thank you for standing by. Welcome to the STAAR Surgical First Quarter 2019 Financial Results Conference Call. During today's presentation, all parties will be in a ...